DRMA · Company research

Dermata Therapeutics, Inc. Common Stock (DRMA): Valuation Analysis

Available valuation snapshots and ratios; unavailable metrics remain blank.

RESEARCH CONTEXT

Understand the numbers

Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.

1records availableHealthcare

Valuation Analysis data

Database-backed records only

1 rows
valuation datepricemarket capenterprise valuepeforward pepegprice salesprice bookprice fcf
Oct 8, 20261.12$4,514,937.57-2430344.43————0.70402860719073420050—

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.